Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
Key Highlights
- ➤PAPZIMEOS Q3 net revenue reached $72.9 million, up 37% sequentially
- ➤Precigen achieved positive cash flow a quarter ahead of schedule
- ➤Precigen reported $35.8 million net income, or $0.08 per diluted share
- ➤PAPZIMEOS treatment surpassed 500 patients since its August 2025 approval
- ➤AdenoVerse received FDA Platform Technology Designation, supporting future product development
Expert Statements
Helen Sabzevari, Chief Executive Officer of Precigen
“We have established an exceptional position of strength, with commercial momentum and a proven strategy driving our next phase of growth,”
Helen Sabzevari, Chief Executive Officer of Precigen
“We achieved positive cash flow ahead of guidance, and PAPZIMEOS' adoption trajectory puts us well on our way to realizing its blockbuster potential,”
Helen Sabzevari, Chief Executive Officer of Precigen
“underscores the high bar PAPZIMEOS has established for treating RRP”
Helen Sabzevari, Chief Executive Officer of Precigen
“Our strategy”
Helen Sabzevari, Chief Executive Officer of Precigen
“was built not simply to be first, but to establish enduring leadership in RRP based on four pillars: (1) PAPZIMEOS' efficacy, safety, durability and ease of administration; (2) its regulatory foundation; (3) its commercial infrastructure; and (4) our ability to execute.”
Helen Sabzevari, Chief Executive Officer of Precigen
“We are confident that PAPZIMEOS will remain the preferred treatment of choice and continued market leader.”
GERMANTOWN, MD / ACCESS Newswire / November 10, 2026 / Precigen Inc. (Nasdaq:PGEN) reported sharply improved third-quarter results late last week, driven by continuing rapid uptake of its flagship therapy PAPZIMEOS(®), as the company achieved positive cash flow a quarter ahead of schedule and posted its second consecutive profitable period. The company's third-quarter PAPZIMEOS net revenue of $72.9 million was up 37% sequentially, bringing cumulative product revenue since launch to approximately $151 million.
Net income for the period was $35.8 million, or $0.08 per diluted share. Cash, cash equivalents and investments stood at $51 million.
Get started
Create a free account to read the full story.